Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCFD4514S intravitreal injections for geographic atrophy
2010-019183-36Phase 2Completed
- Sponsor
- Genentech
- Start
- Oct 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of lampalizumab in geographic atrophy (GA) and age-related macular degeneration (AMD) (3 arms), sponsored by Genentech. Primary endpoint: Growth rate of geographic atrophy lesion area from baseline. Started Oct 2010; status: completed.
02
Drugs
lampalizumab
03
Conditions
geographic atrophy (GA)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2010-019183-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019183-36.